Nargenicin is a macrolide antibiotic that selectively inhibits the growth of S. aureus, methicilin resistant S. aureus (MRSA), and M. luteus (MICs = 0.6, 0.3, and 2.5 µg/ml, respectively) over a panel of 11 Gram-positive and Gram-negative bacteria (MICs = >80 µg/ml). [1] It dose-dependently inhibits S. aureus DnaE in the presence of DNase I-activated DNA and E. coli DnaE when used at concentrations of 0.00001-0.1 and 0.01-100 µg/mL, respectively. [2] In murine BV-2 microglial cells, nargenicin (1 µM) inhibits cytokine expression and nitric oxide production induced by LPS.[3] Nargenicin (200 µM), when used in combination with 1,25-dihydroxyvitamin D3 or all-trans retinoic acid , reduces cell proliferation by 37-47% and increases cell differentiation by 82-85% in HL-60 human myeloid leukemia cells.[4]
